Asthma Drug Slows Down Retinopathy Changes in Type 1 Diabetes

Montelukast, one of the commonly used asthma medication found to slow down eye changes in type-1 diabetes by disrupting the signaling of inflammatory molecules called leukotrienes.

Asthma medication named montelukast (brand name Singulair) inhibits early changes in diabetic retinopathy in type 1 diabetes, according to the researchers from University Hospitals Rainbow Babies, Children’s Hospital and Case Western Reserve University School of Medicine.

The study which was done in a mouse model got published in the journal Diabetes.

Intermittent Montelukast Compared to Placebo in Children Wheeze
A study compared effectiveness of intermittent montelukast with placebo in reducing wheezing episodes in 1358 children aged 10 months to 5 years and whether genotype determined the patient outcome.

TOP INSIGHT

Montelukast is safe and effective in both preventing and delaying intervention approaches for retinopathy, benefiting newly-diagnosed and chronic patients.
Read More..

"We found that montelukast (Singulair) was able to disrupt the signaling of inflammatory molecules called leukotrienes. This disruption significantly reduced small blood vessel and nerve damage that we see in the early stages of diabetic retinopathy," said senior author Rose Gubitosi-Klug, M.D., Ph.D., Chief of Pediatric Endocrinology at UH Rainbow and the William T. Dahms Professor of Pediatrics at CWRU School of Medicine.

"While most therapies target the late stages of the eye disease in diabetes, these findings offer a much-needed approach to treat the disease much earlier."

"The re-purposing of a medication already FDA-approved for use in children and adolescents sets the stage for rapid translation of these animal model findings to human subjects," said Dr. Gubitosi-Klug. "The daily dose equivalent used in the current study is similar to the once daily dose used in the treatment of asthma. Reassuringly, in our diabetes model as in asthma studies, this dose allows effective suppression of chronic inflammation, which can prevent pathology, but avoids complete inhibition of inflammation, which can compromise innate immunity."

"Moreover, montelukast was efficacious in both prevention and delayed intervention approaches, which implies relevance to patients with newly-diagnosed diabetes as well as individuals living with diabetes of longer duration," she said. "Thus, there is promise that a safe treatment that effectively stabilizes airways in asthma may also preserve small blood vessels and nerve cells in diabetes."

Source-Eurekalert